Stockreport

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today® [Yahoo! Finance]

Tiziana Life Sciences Ltd - Common Shares  (TLSA) 
PDF independent of relapse (PIRA) - - Data presented in a platform session at the Annual Meeting of the American Academy of Neurology in Denver, Colorado - NEW YORK, April [Read more]